Recurrence of original disease and secondary malignancy are both important causes of unsuccessful SCT. In both cases the malignant clone is host derived. On the other hand, donor cell leukemia is driven by the graft. This is very infrequent and only partially understood.
Recurrence of original disease and secondary malignancy are both important causes of unsuccessful SCT. In both cases the malignant clone is host derived. On the other hand, donor cell leukemia is driven by the graft. This is very infrequent and only partially understood. 1 A third and different scenario is the inadvertent transmission of occult leukemia from the donor. These cases are even more rare and raise major ethical considerations concerning the patient, the donor, the doctors and the BM registry systems. [2] [3] [4] We have recently observed an atypical clinical case of inadvertent transmission of occult CML with allo-SCT. A 48-year-old male with no relevant medical past history was diagnosed with smoldering myeloma in 2004. First signs of progression were noted in September 2008 and at this time cytogenetic analysis revealed complex karyotype with: del13q14, three copies of 17 chromosomes, relative deletion of TP53 gene and a translocation involving 14q32. The first-line treatment was thalidomide plus dexamethasone, and after achieving a very good PR the patient was referred to high-dose melphalan conditioning regimen and auto-SCT. He maintained a very good PR for 2 years. At this point signs of aggressive progression led to second-line chemotherapy with bortezomib plus dexamethasone. The patient achieved a very good PR. Considering that this was a young patient with poor cytogenetic prognosis who had an HLAmatched sister, it was decided to proceed with the treatment with allogeneic peripheral SCT from the related donor.
The donor was a healthy female with no relevant medical history. Donor routine workup analyses were unremarkable. A reduced-intensity conditioning regimen with fludarabine and BU was performed. CsA and mycophenolate mofetil were used as GVHD prophylaxis. There were no remarkable toxicities after this procedure.
One month after transplant the patient had a very good PR, was a complete chimera and the 20 metaphases analyzed by conventional cytogenetics had a normal female karyotype (46,XX).
Three months later the cytogenetic analysis revealed 16 metaphases with a complex female karyotype that included t(9;22). The complex karyotype was: 46,XX,del(1)(p36),der(9) t(1;9)(p36;q34),der(22)t(9;22)(q34;q11.2)add(9)(q34). With further genetic studies including chromosome painting (FISH WCP1, WCP9, WCP22, Metasystems, Altlussheim, Germany): 46,XX,del(1) (p36),der(9)t(1;9)(p36;q34),ins(22;?)(q11.2;?) [3] .ish,der(1)t(1;9)(p36.1; q34)(wcp1+,wcp9+),der(9)t(1;9)(p36.2;q34)(wcp9+,ABL1+,wcp1+),der (22)(22pter → 22q11.2::9q34 → 9q34::1p36.1 → 1p36.2::22q11.2 → 22 qter)(wcp22+,BCR+,ABL1+,wcp1+,wcp22+). FISH analysis revealed 7% of nucleus with del13q14 and 36% with BCR-ABL. Qualitative PCR analyses revealed the presence of BCR-ABL1 p210 (b2a2).
The donor was contacted and agreed to submit herself to BCR-ABL screening even though she was asymptomatic and maintained unremarkable blood analysis. She had the same complex karyotype and the quantitative RT-PCR of BCR-ABL1 was 57.3% (normalized international BCR-ABL). She was diagnosed with molecular CML. Six months later the patient remained with normal blood count and cytogenetic analysis revealed 30 metaphases with a normal male karyotype, 25 complex female karyotype with t(9;22) and 4 with a normal female karyotype. FISH analysis was consistent with 9% of the nuclei showing del13q14. Quantitative analysis of BCR-ABL1 was 23.7% (normalized international BCR-ABL). The donor maintained a normal blood count and a detectable BCR-ABL1 translocation on cytogenetic analysis.
It was discussed and decided among the patient, the donor and the medical team to start imatinib 400 mg/day in both siblings. Currently (24 months after transplantation and 19 months after imatinib), the patient and the donor have major molecular responses. Also, the patient is in CR from multiple myeloma. Amelogenin gene analysis for the assessment of chimerism was performed and the patient was a complete chimera. It is relevant to consider that a sclerodermic chronic GVHD was diagnosed 12 months after transplantation and is under treatment with CsA and corticotherapy, with gradual improvement.
In conclusion, one should always be aware of the possibility of occult neoplasms in the donor, even though only rare reports are available in the literature. Striking ethical concerns arise in this setting as well as many questions about the best therapeutic choice for both patients and donors. It is also interesting to consider the actual donor workup and the eventual need for new reliable methods to prevent such events. As case reports appear in the literature one speculates whether the growing molecular knowledge of diseases will contribute to changing the donor's workup in the future.
Written informed consent was obtained from the patient for publication of this letter. A copy of the written consent is available upon request.
